Evidence map›Paper›PMID 36595890›Full record

ArticleSTAR protocols2022

Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy.

Joseph D Butner, Maguy Farhat, Vittorio Cristini, Caroline Chung, Zhihui Wang

Abstract read
In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joseph D ButnerMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA. Electronic address: jbutner@houstonmethodist.org.
Maguy FarhatDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Vittorio CristiniMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA; Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA; Physiology, Biophysics, and Systems Biology Program, Graduate School of Medical Sciences, Weill Cornell Medicine, New York, NY 10065, USA.
Caroline ChungDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: cchung3@mdanderson.org.
Zhihui WangMathematics in Medicine Program, Houston Methodist Research Institute, Houston, TX 77030, USA; Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10065, USA; Department of Medical Education, Texas A&M University School of Medicine, Bryan, TX 77807, USA. Electronic address: zwang@houstonmethodist.org.

Funding

Ultra-long Acting Transcutaneously Refillable Islatravir Nanofluidic Implant for HIV Pre-ExposureR01AI165372 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GRATTONI, ALESSANDRO · 2022 to 2025
$4.5M
Vascularized NICHE with local immunosuppression for cell replacement for Type 1 diabetesR01DK133610 · NIDDK · METHODIST HOSPITAL RESEARCH INSTITUTE · PI Alessandro Grattoni, NORMA S. KENYON · 2022 to 2026
$4.3M
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate CancerR01CA226537 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI ARAP, WADIH, BRINKER, C JEFFREY · 2018 to 2022
$3.2M
Vascularized Islet transplantation NICHE with local immunosuppression for the treatment of type 1 diabetesR01DK132104 · NIDDK · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GRATTONI, ALESSANDRO, NICHOLS, JOAN ELIZABETH · 2022 to 2025
$2.8M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancerR01CA253865 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI OZPOLAT, BULENT, WANG, ZHIHUI · 2021 to 2025
$2.0M
NCI NIH HHS R01 CA222007NCI NIH HHS R01 CA226537NCI NIH HHS R01 CA253865NIAID NIH HHS R01 AI165372NIDDK NIH HHS R01 DK132104NIDDK NIH HHS R01 DK133610
6 · The paper itself

Abstract

This protocol describes the application of a mechanistic mathematical model of immune checkpoint inhibitor (ICI) immunotherapy to patient tumor imaging data for predicting solid tumor response and patient survival under ICI intervention. We describe steps for data collection and processing, data pipelines, and approaches to increase precision. The protocol is highly predictive as early as the first restaging after treatment start and can be used with standard-of-care imaging measures. For complete details on the use and execution of this protocol, please refer to Butner et al. (2020)

Indexed as

Immune Checkpoint InhibitorsImmunotherapyData CollectionHumansImmune Checkpoint InhibitorsBiotechnology and bioengineeringCancerHealth SciencesImmunologySystems biology

Identifiers

PMID36595890
PMCPMC9719106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.